Navigation Links
GDFII/L&P Confirms Target Date Extension Of U.S. ITC Sucralose Ruling
Date:3/26/2009

Leading Sucralose manufacturer Guangdong Food Industry Institute/L&P Food Ingredient Co. Ltd. (GDFII/L&P) today announced that the U.S. International Trade Commission (ITC) in Washington D.C. has extended the target date of its final decision in the sucralose case, from March 25 to April 3. This Section 337 patent dispute (docket# 337-TA-604) was filed against the company by its main competitor, Tate & Lyle Corporation (T&L)

Exeter, California (PRWEB) March 26, 2009 -- Leading Sucralose manufacturer Guangdong Food Industry Institute/L&P Food Ingredient Co. Ltd. (GDFII/L&P) today announced that the U.S. International Trade Commission (ITC) in Washington D.C. has extended the target date of its final decision in the sucralose case, from March 25 to April 3. This Section 337 patent dispute (docket# 337-TA-604) was filed against the company by its main competitor, Tate & Lyle Corporation (T&L).

"GDFII/L&P was the first company to manufacture sucralose outside of the U.S.A and continues to be committed to meeting its customer needs of high capacity and superior grade sucralose in the growing sucralose market in the United States and elsewhere, and remains confident of a positive outcome once the ITC issues its final determination," notes Mr. Sanyong Wang, a corporate officer of GDFII/L&P.

Mr. Bassam Faress, spokesperson of GDFII/L&P and Director of Sales/Marketing at Ingredients Specialties, Inc., a global alliance partner of GDFII/L&P, adds "we continue to look forward to this anticipated positive final ruling as we move ahead with our strategic marketing and expansion plans for Sucralose."

The U.S. ITC governs investigations into allegations of unfair trade practices and had in its September 2008 initial determination issued by Administrative Law Judge Charles E. Bullock of the ITC, noted that GDFI
'/>"/>

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Page: 1 2

Related biology technology :

1. Mylan Confirms Four First-to-File Challenges
2. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
3. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
4. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
5. Barr Confirms Patent Challenge of Sensipar(R) Tablets, 30mg, 60mg and 90mg
6. Brazilian Sugarcane Industry: OECD Report Confirms Overall Benefits of Brazilian Sugarcane Ethanol
7. ATS Medical Confirms Excellent Durability of the ATS Open Pivot Mechanical Heart Valve
8. Superior Patient Clinical Outcomes Confirms DaVitas Leadership Position on Quality Dialysis Care
9. ProMetic Further Confirms Performance of Prion Capture Resin at the Recovery of Biological Products Conference
10. Barr Confirms Patent Challenge of Prevacid(R) SoluTab(TM) Delayed-Release Orally Disintegrating Tablets, 15mg and 30mg
11. Clarification on Press Release Issued Earlier Today: Targeted Genetics Confirms Positive, Interim Phase 1/2 Study Findings
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
GDFII/L&P Confirms Target Date Extension Of U.S. ITC Sucralose Ruling
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... Carahsoft and CDS Federal Services have scheduled ... 2pm EST (11am PST), “Natural Language Processing: Converting Raw ... technology can turn raw, heterogeneous data into actionable knowledge ... online webinar will last approximately one hour. , Synopsis: ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider of ... regulatory, business, and media events in the United States ... former associate Virginia Cox , JD, is returning to the ... Virginia Cox re-joins 3D after more than two years of ...
Breaking Biology Technology:Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2
... NEW YORK, March 1, 2012 Reportlinker.com ... is available in its catalogue: ... http://www.reportlinker.com/p0788386/Global-Biotechnology-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biotechno The global outlook series ... anecdotes, market briefs, and concise summaries of ...
... 2012  Receptos Inc. today announced that the company is scheduled ... Care Conference at noon EST on Wednesday, March 7, 2012, ... Hasnain, president and chief executive officer, will provide an overview ... programs. "This is an exciting time at ...
... Laboratories, Inc. (OTCBB: UGNE), a leader in the design, ... that the Company,s senior management team will host a ... 8, 2012 at 11 a.m. ET to discuss fourth ... Interested participants and investors may access the conference call ...
Cached Biology Technology:Global Biotechnology Industry 2Global Biotechnology Industry 3Global Biotechnology Industry 4Global Biotechnology Industry 5Global Biotechnology Industry 6Receptos to Present at the Cowen and Company 32nd Annual Health Care Conference 2Unigene to Announce Fourth Quarter and Full-Year 2011 Financial Results on March 8, 2012 2
(Date:4/23/2014)... "playwright" to their resumes in an effort to aid ... ethical issues as genomic science transitions to bedside healthcare, ... , Until now the plays of Karen H. ... and by, their peers and others in the genomics ... With Oxford University Press, publication of the book ...
(Date:4/23/2014)... is available in French and German . ... female? In humans and other mammals, the difference between sexes depends ... is present only in males, where the two sexual chromosomes are ... Y is ultimately responsible for all the morphological and physiological differences ... the case. A very long time ago, the X and Y ...
(Date:4/23/2014)... most in their mid-thirties and forties, face a ... within two decades. "Mutant" protein clusters, long blamed ... been the primary focus of therapies in development ... from Prof. Gerardo Lederkremer and Dr. Julia Leitman ... and Immunology, in collaboration with Prof. Ulrich Hartl ...
Breaking Biology News(10 mins):Bioethicists use theatrical narratives to bridge the gap between society and science 2Bioethicists use theatrical narratives to bridge the gap between society and science 3Male or female? 2Male or female? 3On the defensive 2On the defensive 3
... nanometer and micron size scales could play a key ... improve the reliability, reduce the size and lower the ... by a team of scientists from the Georgia Tech ... the Naval Surface Warfare Center, the highly-uniform copper structures ...
... treat certain cancers and rheumatoid arthritis appears to greatly ... Medicine researchers report in the Journal of Clinical Investigation. ... continue to be observed long after the antibody is ... antibody, rituximab (anti-CD20), depletes B cells. Experimental evidence in ...
... or physical disabilities should not resort to a ... University. Lori Marino, senior lecturer in the Neuroscience ... Lilienfeld, professor in the Department of Psychology, to ... purveyors of what is known as dolphin-assisted therapy ...
Cached Biology News:Unique porous copper structure enables new generation of military micro-detonators 2Unique porous copper structure enables new generation of military micro-detonators 3Cancer and arthritis therapy may be promising treatment for diabetes 2Dolphin 'therapy' a dangerous fad, Emory researchers warn 2Dolphin 'therapy' a dangerous fad, Emory researchers warn 3
Rabbit polyclonal to Presenilin 1, prediluted ( Abpromise for all tested applications). entrezGeneID: 5663 SwissProtID: P49768...
Mouse monoclonal [LPL4A.1] to Plastin L ( Abpromise for all tested applications). SwissProtID: P13796...
... designed for use with the ProQuest Two-Hybrid ... contains deletions in the endogenous GAL4 and ... systems. The strain also has leu2 and ... and prey vectors. MaV203 contains three GAL4 ...
Request Info...
Biology Products: